Skip to main content
Loading
Sign In
Families and Youth
Toggle
Advocacy
Ethics
Facts for Families
Family Resources
Getting Help
Resource Centers
Youth Resources
Support AACAP
Medical Students and Residents
Toggle
Child Psychiatry Residents (Fellows)
Early Career Psychiatrists
Medical Student Resources
Member Resources
Toggle
Advocacy
Assembly of Regional Organizations
Award Opportunities
Become a Member
Clinical Practice Center
CPT and Reimbursement
Early Career Psychiatrists
Education Center
Ethics
International
Job Source
Life Members
Maintenance of Certification
Resources for Primary Care
Toggle
Advocacy and Policy
Become a Member
Clinical Practice Center
Ethics
Information for Patients and Their Families
Integrating Mental Health Care into the Medical Home
Practice Parameters and Resource Centers
CME & Meetings
Toggle
2019 Annual Meeting
2019 Psychopharmacology Update Institute
2019 Annual Review Course
2018 Annual Meeting
2018 Online Annual Review Course
Learning on Demand
Maintenance of Certification and Lifelong Learning Modules
Online CME
Pathways
My Profile
Store
Cart
Donate
About AACAP
Toggle search
Toggle navigation
Quick Links
Family Resources
Resource Centers
Youth Resources
Child and Adolescent Psychiatrist Finder
ADHD Medication
AACAP Testimony at the March 22 FDA Pediatric Advisory Committee Meeting
3/22/06
AACAP Statement on FDA Advisory On Methylphenidate
3/22/06
FDA Statement on Adderall
Canadian Advisory
AACAP President's Email to Members
Cardiovascular Monitoring of Children and Adolescents Receiving Psychotropic Drugs
American Heart Association (see Other Resources below), as reprinted in JAACAP, 1999
{1}
##LOC[OK]##
{1}
##LOC[OK]##
##LOC[Cancel]##
{1}
##LOC[OK]##
##LOC[Cancel]##
